RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2017; 117(10): 1840
DOI: 10.1160/TH17-08-0573
DOI: 10.1160/TH17-08-0573
Invited Editorial Focus
Accumulating data on rivaroxaban for venous thromboembolism in clinical practice
Weitere Informationen
Publikationsverlauf
Received:
20. August 2017
Accepted after major revision:
24. August 2017
Publikationsdatum:
08. November 2017 (online)
-
References
- 1 Schulman S, Singer D, Ageno W. et al. NOACs for treatment of venous thromboembolism in clinical practice. Thromb Haemost 2017; 117: 1317-1325.
- 2 Bauersachs R, Berkowitz SD, Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
- 3 Buller HR, Prins MH, Lensing AW. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
- 4 Coleman CI, Bunz TJ, Turpie AGG. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Thromb Haemost 2017; 117: 1841-1847.
- 5 Sindet-Pedersen C, Pallisgaard JL, Staerk L. et al. Comparative safety and effectiveness of rivaroxaban versus vitamin K antagonists in patients with venous thromboembolism – A Danish nationwide registry-based study. Thromb Haemost 2017; 117: 1182-1191.